Biocardia stock.
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ...
The estimated Net Worth of Simon H Stertzer is at least $1.35 Millón dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,277,638 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.Nov 15, 2023 · BioCardia, Inc. price | BioCardia, Inc. Quote Zacks Rank & Other Stocks to Consider. BioCardia currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the overall healthcare sector ... The estimated Net Worth of Peter Altman is at least $875 mil dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $197,402 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer y Director at BioCardia.A. BioCardia ( BCDA) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $357K, which beat ...
Looking to buy BCDAW Stock? View today's BCDAW stock price, trade commission-free, and discuss BioCardia Inc. - Warrants (26/07/2022) stock updates with the investor community.
BioCardia (NASDAQ:BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...
Insiders trading at BioCardia. Over the last 7 years, insiders at BioCardia have traded over $2,500,000 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer, and Richard M Krasno.On average, BioCardia executives and independent …With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...6 hari yang lalu ... GlobeNewswire. BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data ...
Nov 29, 2023 · See the latest BioCardia Inc stock price (BCDA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 14d Why Beyond Air Shares Are Trading Lower By Around 37%?
According to the issued ratings of 2 analysts in the last year, the consensus rating for BioCardia stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for BCDA. The average twelve-month price prediction for BioCardia is $4.00 with a high price target of $4.00 and a low price target of $4.00.8 Nov 2023 ... Stock name: BCDA, Stock Code: BCDA, Company: BioCardia, Inc., Sector: Healthcare.BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Website. n/a. 33. Peter Altman. https://www.biocardia.com. BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of ...Nov 24, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmo... SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor …
Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.BioCardia (NASDAQ:BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...BioCardia (NASDAQ:BCDA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment?We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.The FDA approved BioCardia Inc's (NASDAQ: BCDA) Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for ischemic heart failure. The currently ongoing CardiAMP ...BioCardia Inc (BCDA) stock is unmoved 0% while the S&P 500 is higher by 1.44% as of 4:00 PM on Monday, Nov 13. BCDA is unmoved $0.00 from the previous closing price of $0.40 on volume of 39,170,298 shares. Over the past year the S&P 500 has gained 13.09% while BCDA has fallen -78.61%. BCDA lost -$0.63 per share the over the last 12 months.
Overview News BioCardia Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-0.63 Market Cap $14.02 M 21.62 M Public Float 10.05 M Yield BCDA is...
BioCardia (Nasdaq:BCDA) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech BioCardia NasdaqCM:BCDA …BioCardia Inc. analyst ratings, historical stock prices, earnings estimates & actuals. BCDA updated stock price target summary.Find the latest BioCardia, Inc. (6JU.F) stock quote, history, news and other vital information to help you with your stock trading and investing.The main U.S. stock indexes were poised for strong opening gains on Tuesday after cooler-than-expected inflation data boosted expectations that the Federal Reserve was done raising interest rates.At 9:12 ET, Dow e-minis (1YMc1) were up 1.03% at 34,738. ... ** BioCardia BCDA: up 263.4% premarket. BUZZ - Rises on FDA's nod to …SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...Nov 7, 2023 · BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last recorded price of $0.42.
Overview News BioCardia Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-0.63 Market Cap $14.02 M 21.62 M Public Float 10.05 M Yield BCDA is...
Stock Price Forecast. The 1 analysts offering 12-month price forecasts for BioCardia Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate ...
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%?About BioCardia. BioCardia, Inc., headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogeneic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases.SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...The estimated Net Worth of Richard M Krasno is at least $411 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $140,700 and over the last 16 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.BioCardia Inc. () Stock Market info Recommendations: Buy or sell BioCardia stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the BioCardia share forecasts, stock quote and buy / sell signals below.According to present data BioCardia's BCDA shares and potentially its market environment have been in bearish …BioCardia, Inc. (NASDAQ:NASDAQ:BCDA) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ETCompany ParticipantsMiranda Peto - Investor RelationsPeter...15 Nov 2023 ... BioCardia Inc (BCDA) is lower by Wednesday morning, with the stock declining -4.67% in pre-market trading to 1.02.If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.The estimated Net Worth of Simon H Stertzer is at least $1.55 Миллион dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,476,667 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards …Nov 14, 2023 · The FDA approved BioCardia Inc's (NASDAQ: BCDA) Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for ischemic heart failure. The currently ongoing CardiAMP ... SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards …
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ... BioCardia's stock was trading at $0.8269 at the start of the year. Since then, BCDAW stock has decreased by 86.7% and is now trading at $0.11. View the best growth stocks for 2023 here. This page (NASDAQ:BCDAW) was last updated on 10/17/2023 by MarketBeat.com Staff. Get 30 Days of MarketBeat All Access Free.Get the latest BioCardia, Inc. (BCDA) stock news and headlines to help you in your trading and investing decisions. ... 2023 BioCardia, Inc. reports earnings inline with expectations. Reported EPS ...Instagram:https://instagram. trading analytics softwarestocks lowerbest variable life insurance policiestgb 16 Nov 2023 ... ... $BCDA STOCK ANALYSIS | BIOCARDIA STOCK Related topics : stock analysis stock chart stock news best stock best stocks bcda stock ... my digital money reviewshow do i buy nintendo stock Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled ... ffo for reits Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,611,493 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia. Wallmine is a radically better financial terminal. Sign up in seconds, it's free!Stock split history for BioCardia since 2019. Prices shown are actual historical values and are not adjusted for either splits or dividends.Nov 20, 2023 · The stock of BioCardia Inc. (BCDA) has seen a 84.85% increase in the past week, with a 84.37% gain in the past month, and a -16.66% decrease in the past quarter. The volatility ratio for the week is 30.21%, and the volatility levels for the past 30 days are at 12.77% for BCDA. The simple […]